New data for Cimzia® (certolizumab pegol) showed a rapid and sustained response in Japanese rheumatoid arthritis (RA) patients unresponsive to or unable to take methotrexate (MTX) therapy
New data from REALISTIC study showed Cimzia® (certolizumab pegol) provided rapid and sustained efficacy, over 28 weeks, in a broad population of patients with moderate to severe rheumatoid arthritis (RA) including those who discontinued prior anti-TNF the